DK1176964T3 - Brug af ET743 til behandling af cancer - Google Patents

Brug af ET743 til behandling af cancer

Info

Publication number
DK1176964T3
DK1176964T3 DK00927584T DK00927584T DK1176964T3 DK 1176964 T3 DK1176964 T3 DK 1176964T3 DK 00927584 T DK00927584 T DK 00927584T DK 00927584 T DK00927584 T DK 00927584T DK 1176964 T3 DK1176964 T3 DK 1176964T3
Authority
DK
Denmark
Prior art keywords
cancer
treatment
Prior art date
Application number
DK00927584T
Other languages
Danish (da)
English (en)
Inventor
Esteban Cvitkovic
Jean Louis Misset
Angela Bowman
George Demetri
Cecilia Guzman
Jose Jimeno
Lazaro Luis Lopez
C Twelves
HOFF Daniel VON
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of DK1176964T3 publication Critical patent/DK1176964T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
DK00927584T 1999-05-13 2000-05-15 Brug af ET743 til behandling af cancer DK1176964T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound

Publications (1)

Publication Number Publication Date
DK1176964T3 true DK1176964T3 (da) 2007-01-15

Family

ID=27546594

Family Applications (3)

Application Number Title Priority Date Filing Date
DK06014005.0T DK1716853T3 (da) 1999-05-13 2000-05-15 Behandling af cancer i menneskekroppen ved anvendelse af ET743
DK06011784T DK1702618T3 (da) 1999-05-13 2000-05-15 Brug af ET743 i kombinationsterapi med dexamethason til behandling af cancer
DK00927584T DK1176964T3 (da) 1999-05-13 2000-05-15 Brug af ET743 til behandling af cancer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK06014005.0T DK1716853T3 (da) 1999-05-13 2000-05-15 Behandling af cancer i menneskekroppen ved anvendelse af ET743
DK06011784T DK1702618T3 (da) 1999-05-13 2000-05-15 Brug af ET743 i kombinationsterapi med dexamethason til behandling af cancer

Country Status (32)

Country Link
US (1) US8119638B2 (cs)
EP (3) EP1176964B8 (cs)
JP (2) JP2002544231A (cs)
KR (1) KR20020019914A (cs)
CN (2) CN100477993C (cs)
AR (1) AR028476A1 (cs)
AT (3) ATE375795T1 (cs)
AU (2) AU777417B2 (cs)
BG (1) BG65680B1 (cs)
BR (1) BR0010531A (cs)
CA (1) CA2373794C (cs)
CY (4) CY1105818T1 (cs)
CZ (1) CZ301482B6 (cs)
DE (4) DE60030554T8 (cs)
DK (3) DK1716853T3 (cs)
ES (2) ES2272279T3 (cs)
FR (1) FR08C0013I2 (cs)
HU (2) HU229866B1 (cs)
IL (2) IL146434A0 (cs)
LU (1) LU91418I2 (cs)
MX (1) MXPA01011562A (cs)
MY (1) MY164077A (cs)
NL (1) NL300337I2 (cs)
NO (2) NO324564B1 (cs)
NZ (1) NZ515423A (cs)
PL (1) PL198185B1 (cs)
PT (3) PT1716853E (cs)
SI (3) SI1702618T1 (cs)
SK (1) SK287580B6 (cs)
TR (1) TR200103819T2 (cs)
UA (1) UA74782C2 (cs)
WO (1) WO2000069441A1 (cs)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US20040108086A1 (en) * 2000-11-06 2004-06-10 Naoto Takahashi Effective antitumor treatments
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
BR0213424A (pt) * 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) * 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
MX2007000360A (es) * 2004-07-09 2007-06-12 Pharma Mar Sa Marcadores moleculares de pronostico.
AU2005298364B2 (en) * 2004-10-26 2009-03-26 Ortho Biotech Products L.P. Pegylated Liposomal Doxorubicin in combination with Ecteinescidin 743
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2007249281A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
CA2703026A1 (en) * 2007-10-19 2009-04-23 Rafael Rosell Costa Prognostic molecular markers for et-743 treatment
MX381508B (es) * 2016-02-04 2025-03-12 Jiangsu Hengrui Medicine Co Composición farmacéutica inyectable que incluye trabectedina para uso gastrointestinal externo y método para la fabricación de la misma.
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
JP7715732B2 (ja) 2020-04-15 2025-07-30 エバー バリンジェクト ゲーエムベーハー トラベクテジンおよびアミノ酸を含む組成物
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma
US12303506B2 (en) 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
EP0309477B1 (en) * 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
JPH09503743A (ja) * 1993-05-14 1997-04-15 デポテック コーポレーション 神経学的疾患の治療方法
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
ATE405268T1 (de) * 1996-11-05 2008-09-15 Childrens Medical Center Zusammensetzungen enthaltend thalidomide und dexamethason für die behandlung von krebs
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
ES2292237T3 (es) * 1998-04-06 2008-03-01 The Board Of Trustees Of The University Of Illinois Ecteinascidinas semisinteticas.
KR100643092B1 (ko) * 1998-05-11 2006-11-10 파르마 마르, 에스.에이. 엑테인아시딘 743의 대사산물
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
HU230918B1 (hu) 2000-04-12 2019-03-28 Pharma Mar, S.A. Tumorellenes ekteinaszcidinszármazékok
US7247892B2 (en) 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
EP1356097A2 (en) 2000-08-11 2003-10-29 City of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
US20040108086A1 (en) 2000-11-06 2004-06-10 Naoto Takahashi Effective antitumor treatments
WO2002064843A1 (en) 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
AU2002242561A1 (en) 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
BR0213424A (pt) 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1691809A1 (en) 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
MX2007000360A (es) 2004-07-09 2007-06-12 Pharma Mar Sa Marcadores moleculares de pronostico.
CN101068596A (zh) 2004-09-29 2007-11-07 法马马私人股份有限公司 艾可特耐思地作抗炎药
AU2005298364B2 (en) 2004-10-26 2009-03-26 Ortho Biotech Products L.P. Pegylated Liposomal Doxorubicin in combination with Ecteinescidin 743
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
WO2007062413A2 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
AU2007249281A1 (en) 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
DK1716853T3 (da) 2011-06-27
JP5777562B2 (ja) 2015-09-09
HUP0201187A2 (en) 2002-09-28
AU4597500A (en) 2000-12-05
EP1702618B1 (en) 2007-10-17
IL146434A0 (en) 2002-07-25
NO20015516L (no) 2002-01-11
CY2008007I1 (el) 2009-11-04
ES2294756T3 (es) 2008-04-01
EP1716853A2 (en) 2006-11-02
SK287580B6 (sk) 2011-03-04
ATE338552T1 (de) 2006-09-15
IL146434A (en) 2008-03-20
ATE500830T1 (de) 2011-03-15
CN1679631A (zh) 2005-10-12
BG106171A (en) 2002-06-28
LU91418I9 (cs) 2019-01-02
BR0010531A (pt) 2002-06-04
AU2005200180A1 (en) 2005-02-10
KR20020019914A (ko) 2002-03-13
ATE375795T1 (de) 2007-11-15
DE60036826T2 (de) 2008-08-28
EP1176964B1 (en) 2006-09-06
NO2008005I2 (cs) 2010-09-27
PT1176964E (pt) 2007-01-31
NL300337I1 (nl) 2008-05-01
BG65680B1 (bg) 2009-06-30
AU2005200180B9 (en) 2008-05-29
EP1716853B1 (en) 2011-03-09
AU2005200180B2 (en) 2007-12-13
JP2012149095A (ja) 2012-08-09
PL198185B1 (pl) 2008-06-30
CY2008007I2 (el) 2009-11-04
FR08C0013I2 (fr) 2009-10-30
EP1702618A2 (en) 2006-09-20
CZ301482B6 (cs) 2010-03-17
NO324564B1 (no) 2007-11-19
ES2272279T3 (es) 2007-05-01
PT1702618E (pt) 2008-01-11
HUS1500001I1 (hu) 2016-08-29
EP1176964A1 (en) 2002-02-06
CA2373794C (en) 2005-10-11
MY164077A (en) 2017-11-30
SI1702618T1 (sl) 2008-02-29
CA2373794A1 (en) 2000-11-23
US8119638B2 (en) 2012-02-21
HUP0201187A3 (en) 2002-11-28
TR200103819T2 (tr) 2002-04-22
EP1716853A3 (en) 2006-11-15
NL300337I2 (nl) 2008-09-01
NO20015516D0 (no) 2001-11-12
CY1105818T1 (el) 2011-02-02
SI1176964T1 (sl) 2007-02-28
EP1716853B9 (en) 2011-09-28
NO2008005I1 (no) 2008-06-09
NZ515423A (en) 2004-04-30
PL352931A1 (en) 2003-09-22
JP2002544231A (ja) 2002-12-24
DE60036826D1 (de) 2007-11-29
LU91418I2 (fr) 2008-05-13
CY1112753T1 (el) 2016-02-10
PT1716853E (pt) 2011-05-12
CN100477993C (zh) 2009-04-15
US20070275942A1 (en) 2007-11-29
EP1176964B8 (en) 2007-10-10
SK16442001A3 (sk) 2002-03-05
AR028476A1 (es) 2003-05-14
CZ20014081A3 (cs) 2002-11-13
DE60030554T8 (de) 2008-01-10
WO2000069441A1 (en) 2000-11-23
DE60030554D1 (de) 2006-10-19
DE60045720D1 (de) 2011-04-21
DK1702618T3 (da) 2008-02-25
SI1716853T1 (sl) 2011-10-28
CY1107143T1 (el) 2010-07-28
CN1360503A (zh) 2002-07-24
HU229866B1 (en) 2014-10-28
AU777417B2 (en) 2004-10-14
EP1702618A3 (en) 2006-12-27
MXPA01011562A (es) 2002-07-30
FR08C0013I1 (cs) 2008-05-30
DE60030554T2 (de) 2007-09-13
UA74782C2 (uk) 2006-02-15
DE122008000013I1 (de) 2008-08-07

Similar Documents

Publication Publication Date Title
DK1176964T3 (da) Brug af ET743 til behandling af cancer
NO20014379D0 (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
EE200200172A (et) Ühendid isheemia ravimiseks
EE200200673A (et) Kinasoliini derivaadid kasvajate raviks
FI20000863A0 (fi) Uusi hoitomenetelmä
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK2412368T3 (da) Sammensætning til behandling af ar
DE60020327D1 (de) Wasserbehandlungsvorrichtung
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK1223927T3 (da) Anvendelse af retigabin til behandling af neuropatiske smerter
DE60040607D1 (de) Wasserbehandlungseinrichtung
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
EE200200571A (et) Hüdroksüfenüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
DK1150991T3 (da) Præparater til behandling af inflammatoriske reaktioner
NO20022245L (no) Onkolyttiske kombinasjoner for behandling av cancer
NO20020358D0 (no) Anvendelse av etodolac for behandling av kreft
ATE275676T1 (de) Duschkombination
EE200200577A (et) Kinolinüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
EE200200511A (et) Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks
NO20013596D0 (no) Slambehandling
ATE302165T1 (de) Wasserbehandlung
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
DK1224181T3 (da) Substituerede pyrroler som antiproliferative midler til behandling af cancer